Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus R-CHOP in previously untreated ABC-type DLBCL
NCT02285062Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Feb 2015
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-Free Survival at 24.5 months. Started Feb 2015; status: completed.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02285062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02285062.